Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcg vaccine (Sinergium Biotech)
- Development stage
- Unknown
- Lead developer
- SINERGIUM Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
CarciVac is an intravesical immunotherapy consisting of a live-attenuated strain of *Mycobacterium bovis* (Bacillus Calmette-Guérin). Developed by SINERGIUM Biotech, it is indicated for the treatment of non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ (CIS) and superficial papillary tumors (Ta/T1). When administered directly into the bladder, it triggers a robust local immune response, characterized by the recruitment of inflammatory cells and the release of cytokines, which ultimately leads to the targeted destruction of urothelial tumor cells. It is currently approved for use in these indications.
- Brand names
- CarciVac
- Other names
- Bacillus Calmette-Guérin vaccineBCG vaccineBCG immunotherapy
02
Targets
TLR2 (Toll-like Receptor 2)TCR-BCG-pMHC (T-cell receptor recognizing Bacillus Calmette-Guérin-derived peptide–major histocompatibility complex)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR9 (Toll-like receptor 9)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on bcg vaccine (Sinergium Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcg vaccine (Sinergium Biotech).